Thompson D C, Vaisman A, Sakata M K, Wyrick S D, Holbrook D J, Chaney S G
School of Medicine, University of North Carolina, Chapel Hill 27599, USA.
Cancer Chemother Pharmacol. 1995;36(5):439-47. doi: 10.1007/BF00686194.
We examined the intracellular biotransformation products of ormaplatin [(d,l-trans)1,2-diaminocyclohexanetetrachloroplatinum(IV)] (formerly called tetraplatin) in liver, kidney, spleen, small intestine, and plasma of the adult male Fischer 344 rat. Previous studies have established that the rank order of ormaplatin toxicity in Fischer 344 rats is spleen approximately gastrointestinal tract > kidney >> liver. Animals were given tritium-labelled drug i.v. at 12.5 mg/kg, and tissues were harvested 30 min later. The kidney was found to concentrate total and cytosolic platinum to a greater extent than any of the other tissues. The absolute amount of cytosolic platinum, in micrograms per gram tissue, that was irreversibly bound to protein and/or other macromolecules was also greatest in the kidney. However, when the amount bound was expressed as a percentage of the total cytosolic platinum, the kidney was significantly lower than any other tissue. Of the various low molecular mass platinum biotransformation species characterized, by far the most abundant were complexes of platinum with the sulfur-containing molecules cysteine, methionine, and glutathione (GSH). There was more of the methionine complex in the blood plasma than in any of the tissues except for the spleen. No significant differences among the tissues were detected for the dichloro, cysteine, methionine, or the GSH complexes. The tritium-labelled diaminocyclohexane (DACH) carrier ligand appeared to remain stably bound to the platinum while in the plasma, as there was less free DACH ligand detected in plasma ultrafiltrate than in any tissue ultrafiltrate. Among the tissues, the free DACH levels were in the range of 20% of the radioactivity recovered from the HPLC column and were not significantly different. Consequently, neither biodistribution nor tissue-specific biotransformation of ormaplatin provides a ready explanation for the tissue specificity of ormaplatin toxicity in Fischer 344 rats. However, in kidney there was much less of the reactive PtCl2(DACH) species than has previously been reported for the corresponding Pt(NH3)2Cl2 species in cisplatin-treated rats. Thus, these data suggest a possible explanation for differences in nephrotoxicity induced by cisplatin versus that by ormaplatin.
我们研究了成年雄性Fischer 344大鼠肝脏、肾脏、脾脏、小肠和血浆中奥马铂[(d,l-反式)1,2-二氨基环己烷四氯铂(IV)](以前称为四铂)的细胞内生物转化产物。先前的研究已经确定,Fischer 344大鼠中奥马铂毒性的顺序为脾脏≈胃肠道>肾脏>>肝脏。给动物静脉注射12.5mg/kg的氚标记药物,30分钟后采集组织。发现肾脏比其他任何组织更能富集总铂和胞质铂。每克组织中不可逆地与蛋白质和/或其他大分子结合的胞质铂的绝对量在肾脏中也最大。然而,当结合量以总胞质铂的百分比表示时,肾脏明显低于任何其他组织。在已鉴定的各种低分子量铂生物转化物种中,到目前为止最丰富的是铂与含硫分子半胱氨酸、蛋氨酸和谷胱甘肽(GSH)的复合物。血浆中的蛋氨酸复合物比除脾脏外的任何组织都多。在二氯、半胱氨酸、蛋氨酸或谷胱甘肽复合物方面,各组织之间未检测到显著差异。氚标记的二氨基环己烷(DACH)载体配体在血浆中似乎与铂稳定结合,因为在血浆超滤液中检测到的游离DACH配体比在任何组织超滤液中都少。在各组织中,游离DACH水平在从HPLC柱回收的放射性的20%范围内,且无显著差异。因此,奥马铂的生物分布和组织特异性生物转化都不能为Fischer 344大鼠中奥马铂毒性的组织特异性提供现成的解释。然而,肾脏中活性PtCl2(DACH)物种比先前报道的顺铂处理大鼠中相应的Pt(NH3)2Cl2物种要少得多。因此,这些数据为顺铂与奥马铂诱导的肾毒性差异提供了一种可能的解释。